Supreme Court Rejects Drug Makers' Medicare Price Fight

The Supreme Court rejects appeals from drug manufacturers challenging Medicare's price negotiation power, keeping a major piece of the Biden-era drug pricing law intact. The decision is a win for government control over health care costs, but it also means Washington keeps expanding its grip over private industry. Supporters call it consumer relief; critics see another step toward price-setting by federal bureaucrats. Read more about this...